Stock Market News

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

Jun 13, 2025 - 22:00
 0
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
Read More

Tags:

Previous Article

Ye makes surprise appearance at Sean 'Diddy' Combs trial; judge considers removi...

Next Article

Rimini Street: Strategic Growth And Margin Strength

Related Posts

Sony sees profits flat this year

Sony sees profits flat this year

May 14, 2025  0

Volkswagen to 're-engage' in China EV market by third quarter of 2026, CFO tells FT

Volkswagen to 're-engage' in China EV market by third q...

May 13, 2025  0

Trump gives Harvard 30 days to contest end of foreign student enrollment

Trump gives Harvard 30 days to contest end of foreign s...

May 29, 2025  0